HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Leukemia

• Publication date

  2003-08-14

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/sj.leu.2403102PMID 12931228
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia.

  2002cited by this paper
• Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects.

  2002cited by this paper
• The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195.

  2002cited by this paper
• Epothilone B analogue (BMS-247550)-mediated cytotoxicity through induction of Bax conformational change in human breast cancer cells.

  2002cited by this paper
• Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.

  2002cited by this paper
• Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins

  2002cited by this paper
• The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules.

  2002cited by this paper
• Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics.

  2002cited by this paper
• Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening.

  2001cited by this paper
• Apoptosis and the response to anticancer therapy

  2001cited by this paper
• Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during Lymphomagenesis

  2001cited by this paper
• Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3

  2001cited by this paper
• Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells.

  2000cited by this paper
• Clinical studies of antisense therapy in cancer.

  2000cited by this paper
• Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma.

  2000cited by this paper
• Controlling the mitochondrial gatekeeper for effective chemotherapy

  2000cited by this paper
• Mechanisms of apoptosis avoidance in cancer.

  1999cited by this paper
• Bcl‐2 alters the balance between apoptosis and necrosis, but does not prevent cell death induced by oxidized low density lipoproteins

  1999cited by this paper
• Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities.

  1999cited by this paper
• Expression of apoptosis-controlling proteins in acute leukemia cells.

  1999cited by this paper
• Insights from Bcl-2 and Myc: malignancy involves abrogation of apoptosis as well as sustained proliferation.

  1999cited by this paper
• In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95)

  1998cited by this paper
• bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

  1998cited by this paper
• Elucidating the molecular mechanism of the permeability transition pore and its role in reperfusion injury of the heart.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

  1997cited by this paper
• Measurement of spontaneous and therapeutic agent-induced apoptosis with BCL-2 protein expression in acute myeloid leukemia.

  1997cited by this paper
• In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95).

  1996cited by this paper
• Bcl-XL protects cancer cells from p53-mediated apoptosis.

  1995cited by this paper
• Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.

  1994cited by this paper
• Features of apoptotic cells measured by flow cytometry.

  1992cited by this paper
• Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells

  1988cited by this paper

• MicroRNA-143 sensitizes acute myeloid leukemia cells to cytarabine via targeting ATG7- and ATG2B-dependent autophagy

  2020cites this paper
• A proficient microwave synthesis with structure elucidation and the exploitation of the biological behavior of the newly halogenated 3-amino-1H-benzo[f]chromene molecules, targeting dual inhibition of topoisomerase II and microtubules.

  2019cites this paper
• Fall 9-1-2008 Expanding circle of inhibition : small-molecule inhibitors of Bcl-2 asanticancer cell and antiangiogenic agents

  2019cites this paper
• Sequestering survivin to functionalized nanoparticles: a strategy to enhance apoptosis in cancer cells.

  2016cites this paper
• Inhibition of BCL‐2 leads to increased apoptosis and delayed neuronal differentiation in human ReNcell VM cells in vitro

  2016cites this paper
• Fruit Extract from A Sechium edule Hybrid Induce Apoptosis in Leukaemic Cell Lines but not in Normal Cells

  2015cites this paper
• The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma

  2015cites this paper
• Regulation of HA14-1 mediated oxidative stress, toxic response, and autophagy by curcumin to enhance apoptotic activity in human embryonic kidney cells.

  2014cites this paper
• B Cell Lymphoma-2 (BCL-2) Homology Domain 3 (BH3) Mimetics Demonstrate Differential Activities Dependent upon the Functional Repertoire of Pro- and Anti-apoptotic BCL-2 Family Proteins*

  2014cites this paper
• HA 14-1 is able to reconstitute the impaired mitochondrial pathway of apoptosis in renal cell carcinoma cell lines

  2014cites this paper
• Effect of HA14‐1 on Apoptosis‐Regulating Proteins in HeLa Cells

  2014cites this paper
• Mechanisms of CXL017: targeting drug resistant cancer

  2012cites this paper
• Bcl-2 inhibitors: emerging drugs in cancer therapy.

  2012cites this paper
• Targeting the anti-apoptotic Bcl-2 family members for the treatment of cancer.

  2012influential citation
• Casein induces the proliferation of bone marrow mononuclear cells, apoptosis of WEHI-3 leukaemic cells and increased survival in a leukaemia mouse model.

  2012cites this paper
• Apoptosis sensitizers enhance cytotoxicity in hepatoblastoma cells

  2012cites this paper
• Structure-activity relationship (SAR) study of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and the potential of the lead against multidrug resistance in cancer treatment.

  2012cites this paper
• Targeting Bcl-2 in CLL.

  2012cites this paper
• Facile Synthesis of Chrysin-derivatives with Promising Activities as Aromatase Inhibitors†

  2011cites this paper
• The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment.

  2011cites this paper
• Structure-activity relationship and molecular mechanisms of ethyl 2-amino-6-(3,5-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (CXL017) and its analogues.

  2011cites this paper
• Improving VSV virotherapy in chronic lymphocytic leukemia with small-molecule BCL-2 inhibitors

  2011influential citation
• Targeting Bcl-2 Family Proteins in Childhood Leukemia

  2011cites this paper
• Induction of apoptosis by esculetin in human leukemia U937 cells: roles of Bcl-2 and extracellular-regulated kinase signaling.

  2010cites this paper
• The roles of elevated Bcl-2 in ovarian cancer

  2010cites this paper
• HA14-1 sensitizes TNF-alpha-induced apoptosis via inhibition of the NF-kappaB signaling pathway: involvement of reactive oxygen species and JNK.

  2010cites this paper
• Urinary levels of Bcl-2 are elevated in ovarian cancer patients.

  2009cites this paper
• Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells

  2009cites this paper
• Mcl-1 is an important determinant of the apoptotic response to the BH3-mimetic molecule HA14-1 in cisplatin-resistant ovarian carcinoma cells

  2009cites this paper
• Molecular mechanism of drug induced apoptosis and chemoresistance in estrogen receptor alpha +/- breast cancer cell lines: mcf-7 and mda-mb-231

  2009cites this paper
• Small-molecule BH3 mimetics to antagonize Bcl-2-homolog survival functions in cancer.

  2009cites this paper
• Apoptosis of t(14;18)-positive lymphoma cells by a Bcl-2 interacting small molecule

  2009cites this paper
• Dual Mechanisms of sHA 14-1 in Inducing Cell Death through Endoplasmic Reticulum and Mitochondria

  2009cites this paper
• Akt inhibitors induce apoptosis in chronic lymphocytic leukemia cells

  2009cites this paper
• Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells.

  2009cites this paper
• Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?

  2008cites this paper
• Promotion of PDT Efficacy by a Bcl‐2 Antagonist

  2008cites this paper
• Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).

  2008cites this paper
• Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells.

  2008cites this paper
• HA14-1 is Able to Reconstitute the Impaired Mitochondrial Pathway of Apoptosis in Renal Cell Carcinoma Cell Lines

  2008cites this paper
• Targeting the Apoptotic Pathway with BCL-2 Inhibitors Sensitizes Primary Chronic Lymphocytic Leukemia Cells to Vesicular Stomatitis Virus-Induced Oncolysis

  2008cites this paper
• Chelerythrine Induces Apoptosis through a Bax/Bak-independent Mitochondrial Mechanism*

  2008cites this paper
• sHA 14-1, a stable and ROS-free antagonist against anti-apoptotic Bcl-2 proteins, bypasses drug resistances and synergizes cancer therapies in human leukemia cell.

  2008cites this paper
• Expanding circle of inhibition: small-molecule inhibitors of Bcl-2 as anticancer cell and antiangiogenic agents.

  2008cites this paper
• The development of pro-apoptotic cancer therapeutics.

  2008cites this paper
• Inhibitors of the Bcl-2 Protein Family as Sensitizers to Anticancer Agents

  2008cites this paper
• The small-molecule Bcl-2 inhibitor HA14-1 sensitizes cervical cancer cells, but not normal fibroblasts, to heavy-ion radiation.

  2008cites this paper
• Ethyl-2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H- chromene-3-carboxylate (HA 14-1), a prototype small-molecule antagonist against antiapoptotic Bcl-2 proteins, decomposes to generate reactive oxygen species that induce apoptosis.

  2007cites this paper
• Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction

  2007cites this paper
• Selective targeting of apoptotic pathways in follicular lymphoma cells

  2007cites this paper
• HA14-1, a small molecule inhibitor of Bcl-2, bypasses chemoresistance in leukaemia cells.

  2007cites this paper
• Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor

  2007influential citation
• Brefeldin A triggers apoptosis associated with mitochondrial breach and enhances HA14-1- and anti-Fas-mediated cell killing in follicular lymphoma cells.

  2007cites this paper
• Novel Approaches to Induce Apoptosis in Human Follicular Lymphoma Cell Lines

  2007cites this paper
• Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: a promising new approach to the treatment of multidrug resistant cancer.

  2007cites this paper
• HA14-1, a small molecule Bcl-2 antagonist, induces apoptosis and modulates action of selected anticancer drugs in follicular lymphoma B cells.

  2006cites this paper
• Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells.

  2006cites this paper
• Chemoresistance in solid tumours.

  2006cites this paper
• Drug resistance, predictive markers and pharmacogenomics in colorectal cancer.

  2006cites this paper
• Enhanced cellular uptake of Ara‐C via a peptidomimetic prodrug, L‐valyl‐ara‐C in Caco‐2 cells

  2006cites this paper
• Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2.

  2006cites this paper
• Targeting the Bcl-2 family in cancer therapy.

  2006cites this paper
• The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death.

  2006cites this paper
• Sulindac sulfide–induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2

  2005cites this paper
• Antagonistes de Bcl-2, thérapies anticancéreuses alternatives

  2005cites this paper
• Targeting Apoptosis Pathways in Cancer Therapy

  2005cites this paper
• Anaplastic lymphoma kinase and its signalling molecules as novel targets in lymphoma therapy

  2005cites this paper
• The Intrinsic (Mitochondrial) Death Pathway and New Cancer Therapeutics: Bcl-2 Family in Focus

  2005cites this paper
• Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent.

  2005cites this paper
• Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells

  2004cites this paper
• Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy.

  2004cites this paper
• A Bcr/Abl-independent, Lyn-dependent Form of Imatinib Mesylate (STI-571) Resistance Is Associated with Altered Expression of Bcl-2*

  2004cites this paper
• Critical Upstream Signals of Cytochrome c Release Induced by a Novel Bcl-2 Inhibitor*

  2004cites this paper
• Targeting apoptosis pathways in cancer therapy.

  2004cites this paper
• The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism.

  2004cites this paper
• Shooting at survivors: Bcl-2 family members as drug targets for cancer.

  2004cites this paper